BYL719H
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $413,315 | 36 | 3 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $413,315 | 36 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ALPELISIB (BYL719) IN COMBINATION WITH NAB-PACLITAXEL IN PATIENTS WITH ADVANCED TRIPLE NEGATIVE BREAST CANCER WITH EITHER PHOSPHOINOSITIDE-3- | Novartis Pharmaceuticals Corporation | $411,101 | 0 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $2,214 | 3 |
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $413,315
Product Information
- Type Drug
- Total Payments $413,315
- Total Doctors 3
- Transactions 36
About BYL719H
BYL719H is a drug associated with $413,315 in payments to 3 healthcare providers, recorded across 36 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2020 to 2020. In 2020, $413,315 was paid across 36 transactions to 3 doctors.
The most common payment nature for BYL719H is "Unspecified" ($413,315, 100.0% of total).
BYL719H is associated with 2 research studies, including "A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ALPELISIB (BYL719) IN COMBINATION WITH NAB-PACLITAXEL IN PATIENTS WITH ADVANCED TRIPLE NEGATIVE BREAST CANCER WITH EITHER PHOSPHOINOSITIDE-3-" ($411,101).